João M. Santos

1.5k total citations
39 papers, 1.1k citations indexed

About

João M. Santos is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, João M. Santos has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 36 papers in Genetics and 17 papers in Immunology. Recurrent topics in João M. Santos's work include Virus-based gene therapy research (36 papers), CAR-T cell therapy research (36 papers) and Immunotherapy and Immune Responses (13 papers). João M. Santos is often cited by papers focused on Virus-based gene therapy research (36 papers), CAR-T cell therapy research (36 papers) and Immunotherapy and Immune Responses (13 papers). João M. Santos collaborates with scholars based in Finland, Netherlands and France. João M. Santos's co-authors include Akseli Hemminki, Otto Hemminki, Riikka Havunen, Víctor Cervera-Carrascón, Anna Kanerva, Suvi Sorsa, Mikko Siurala, Sadia Zafar, Dafne C.A. Quixabeira and Siri Tähtinen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Methods in enzymology on CD-ROM/Methods in enzymology.

In The Last Decade

João M. Santos

38 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
João M. Santos Finland	18	823	691	366	336	212	39	1.1k
Riikka Havunen Finland	19	934 1.1×	753 1.1×	335 0.9×	375 1.1×	223 1.1×	44	1.1k
Mikko Siurala Finland	18	846 1.0×	694 1.0×	300 0.8×	328 1.0×	198 0.9×	26	986
Minna Oksanen Finland	17	666 0.8×	726 1.1×	210 0.6×	367 1.1×	187 0.9×	24	884
Timo Joensuu Finland	18	668 0.8×	716 1.0×	190 0.5×	367 1.1×	176 0.8×	27	893
Sari Pesonen Finland	16	629 0.8×	734 1.1×	213 0.6×	448 1.3×	206 1.0×	24	947
Amanda Rosewell Shaw United States	14	761 0.9×	722 1.0×	260 0.7×	473 1.4×	123 0.6×	24	1.0k
Roshni Ravindranathan United States	12	805 1.0×	727 1.1×	432 1.2×	337 1.0×	157 0.7×	17	1.1k
Suvi Sorsa Finland	13	623 0.8×	486 0.7×	220 0.6×	239 0.7×	140 0.7×	22	725
Padma Sampath United States	16	597 0.7×	517 0.7×	327 0.9×	280 0.8×	112 0.5×	19	843
Sari Pesonen Finland	20	700 0.9×	659 1.0×	125 0.3×	537 1.6×	219 1.0×	33	1.1k

Countries citing papers authored by João M. Santos

Since Specialization

Citations

This map shows the geographic impact of João M. Santos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by João M. Santos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites João M. Santos more than expected).

Fields of papers citing papers by João M. Santos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by João M. Santos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by João M. Santos. The network helps show where João M. Santos may publish in the future.

Co-authorship network of co-authors of João M. Santos

This figure shows the co-authorship network connecting the top 25 collaborators of João M. Santos. A scholar is included among the top collaborators of João M. Santos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with João M. Santos. João M. Santos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peltola, Katriina, Tuomo Alanko, Teijo Pellinen, et al.. (2025). Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 13(1). e010493–e010493. 2 indexed citations

Grönberg-Vähä-Koskela, Susanna, Dafne C.A. Quixabeira, João M. Santos, et al.. (2025). Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer Immunology Immunotherapy. 74(7). 234–234. 1 indexed citations

Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.

Ellebæk, Eva, Marco Donia, Rikke Løvendahl Eefsen, et al.. (2024). Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Immuno-Oncology Technology. 24. 100726–100726. 2 indexed citations

Quixabeira, Dafne C.A., Susanna Grönberg-Vähä-Koskela, Camilla Heiniö, et al.. (2023). An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage. Frontiers in Immunology. 14. 1171083–1171083. 4 indexed citations

Quixabeira, Dafne C.A., Riikka Havunen, João M. Santos, et al.. (2023). Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Cancer Gene Therapy. 30(12). 1679–1690. 6 indexed citations

Quixabeira, Dafne C.A., Riikka Havunen, João M. Santos, et al.. (2023). Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine. Cancer Gene Therapy. 30(11). 1543–1553. 7 indexed citations

Santos, João M., Dafne C.A. Quixabeira, Susanna Grönberg-Vähä-Koskela, et al.. (2022). Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors. Molecular Therapy — Oncolytics. 28. 59–73. 8 indexed citations

Heiniö, Camilla, Víctor Cervera-Carrascón, João M. Santos, et al.. (2022). Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology. 13. 794251–794251. 32 indexed citations

10.

Quixabeira, Dafne C.A., Víctor Cervera-Carrascón, João M. Santos, et al.. (2022). Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. OncoImmunology. 11(1). 2028960–2028960. 14 indexed citations

11.

Quixabeira, Dafne C.A., João M. Santos, Víctor Cervera-Carrascón, et al.. (2021). Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. Human Gene Therapy. 32(3-4). 178–191. 9 indexed citations

12.

Quixabeira, Dafne C.A., Sadia Zafar, João M. Santos, et al.. (2021). Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in Immunology. 12. 674400–674400. 28 indexed citations

13.

Svane, Inge Marie, João M. Santos, Víctor Cervera-Carrascón, et al.. (2021). 1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes. Annals of Oncology. 32. S864–S864. 4 indexed citations

14.

Zafar, Sadia, Dafne C.A. Quixabeira, João M. Santos, et al.. (2020). Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. Human Gene Therapy. 32(3-4). 192–202. 21 indexed citations

15.

Heiniö, Camilla, Riikka Havunen, João M. Santos, et al.. (2020). TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. Cells. 9(4). 798–798. 33 indexed citations

16.

Santos, João M., Camilla Heiniö, Víctor Cervera-Carrascón, et al.. (2020). Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. Journal for ImmunoTherapy of Cancer. 8(1). e000188–e000188. 56 indexed citations

17.

Cervera-Carrascón, Víctor, Mikko Siurala, João M. Santos, et al.. (2018). TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. OncoImmunology. 7(5). e1412902–e1412902. 90 indexed citations

18.

Havunen, Riikka, João M. Santos, Suvi Sorsa, et al.. (2018). Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 11. 109–121. 45 indexed citations

19.

Santos, João M., Víctor Cervera-Carrascón, Riikka Havunen, et al.. (2018). Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Molecular Therapy. 26(9). 2243–2254. 44 indexed citations

20.

Havunen, Riikka, Mikko Siurala, Suvi Sorsa, et al.. (2017). Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Molecular Therapy — Oncolytics. 4. 77–86. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact